Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 in Relapsed or Refractory Hodgkin Lymphoma
NCT01217229Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2011
- Primary completion
- Apr 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in Hodgkin lymphoma (HL), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2011; status: completed.
02
Drugs
pexidartinib
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01217229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217229.